Ticho Barry 4

What Happened
Ticho Barry, Chief Medical Officer of Stoke Therapeutics (STOK), sold a total of 7,228 shares in open‑market transactions on July 1, 2026. The sales consisted of 6,728 shares at a weighted average price of $32.62 (proceeds ~$219,434) and 500 shares at a weighted average price of $33.27 (proceeds ~$16,634), for combined gross proceeds of approximately $236,068. These were outright sales (not purchases or option exercises), which are often routine cashing‑out events rather than a direct signal of company prospects.

Key Details

• Transaction date: July 1, 2026 (reported on Form 4 filed July 6, 2026)
• Reported prices: weighted averages $32.62 (range $32.18–$33.05) and $33.27 (range $33.23–$33.37)
• Shares sold: 6,728 and 500; total 7,228 shares; total proceeds ≈ $236,068
• Ownership after transaction: Not specified in the excerpt provided (check the full Form 4 for post‑trade beneficial ownership)
• Notable footnotes: at least one sale was executed pursuant to a Rule 10b5‑1 trading plan adopted Nov 19, 2025; weighted average prices reflect multiple executions and the filer offers to provide per‑price details on request
• Timeliness: Form 4 was filed July 6 for trades on July 1 (this is several days after the trade; compare to the SEC two‑business‑day reporting deadline)

Context

• Sales executed under a 10b5‑1 plan are pre‑planned trades and are commonly used by insiders to sell shares without trading based on material nonpublic information. Such sales are typically viewed as routine; they do not by themselves indicate insider conviction about future performance.
• For full context, retail investors should review the complete Form 4 (accession 0001780088-26-000015) for post‑trade ownership and any additional disclosures.